Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pulmonary Disease
Biotech
Santhera loses interest in pulmonary drug to focus on DMD
The biotech has decided its lonodelestat dreams may have to die so vamorolone can fly.
James Waldron
Oct 31, 2022 10:25am
Arrowhead 'changing horses' for ENaC pulmonary program
Feb 3, 2022 11:57am
2 cancer drugs show promise in a hard-to-treat lung disease
Oct 22, 2021 8:35am
ShouTi snags $100M for oral drugs to treat chronic diseases
Oct 20, 2021 8:00am
Lung Therapeutics raises $36M to trial pleural effusion drug
Jun 5, 2019 9:35am
Bayer, Haplogen ink R&D deal for pulmonary diseases
Aug 14, 2018 10:44am
